SOAT1 and T-lymphoblastic lymphoma: Artesunate and ruxolitinib alone and in combination inhibited aberrant activation of the JAK/STAT pathway in T-lymphoblastic lymphoma/leukemia, supporting the value of this combination in patients with JAK/STAT protein mutations.